Xtant Medical Holdings (XTNT) Peer Comparison

$0.38

$-0.10 (-20.73%)

As on 04-Sep-2026 13:34EDT

Market cap

$56 Mln

Revenue (TTM)

$110 Mln

P/E Ratio

--

P/B Ratio

1.4

Div. Yield

0 %

Edit

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	56	12,650	10,638	9,762	9,948
Revenue ($ Mln)	110	1,505	613	2,589	785
Net Profit ($ Mln)	-11.14	160.59	-188.05	222.40	41.54
Net Margin (%)	-10.17	10.67	-30.68	8.59	5.29
RoE (%)	-24.49	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	251.81
Price-To-Book	1.43	8.31	15.27	1.36	4.86

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	109.53	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	44.48	483.98	127.96	1,245.50	384.30
Gross Profit	84.27	942.44	393.22	1,343.60	347.62
Operating Expenses	75.54	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-10.50	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-9.24	203.83	-192.83	350.40	52.15
Provision for Tax	1.90	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-11.14	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	40.02	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	9.69	210.18	135.71	2,116.80	705.49
Current Liabilities	29.96	233.78	102.33	961.30	132.66
Total Liabilities	94.15	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	14.89	630.60	404.74	7,231.50	1,749.63
Current Assets	64.78	1,344.12	515.78	3,020.50	1,200.55
Total Assets	94.15	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	26.01	212.71	102.84	1,203.70	690.94
Net Current Assets	0.00	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	12.55	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	7.90	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-9.57	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	6.30	11.76	-22.53	8.98	1.79
ROE (%)	-24.49	10.86	-28.10	3.04	1.97
ROA (%)	-8.00	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-5.91	13.63	-30.58	-5.99	9.87
Net Margin (%)	-10.17	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	-14.27	17.55	41.55	1.37	16.49
EBIT Growth (%)	-5,780.70	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	-143.11	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-120.01	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-12.61	17.33	-12.65	2.19	2.16

Valuation Ratios

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	23.60	68.93	-34.59	--	189.42
Price / Book Value	1.43	8.31	15.27	--	4.40
Dividend Yield (%)	0.00	0.00	0.00	--	--
EV/EBITDA	-27.37	55.45	-73.80	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.41	0.01	0.00	0.06	0.01
Current Ratio	2.16	5.75	5.04	3.14	9.05
Quick Ratio	1.05	3.86	4.46	2.33	7.64
Interest Coverage	-2.34	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Xtant Medical Holdings (XTNT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	17.73	12.65	22.67	17.06	20.09
Asset Turnover	0.79	0.74	0.59	0.24	0.26
Receivable days	52.45	46.54	60.95	65.39	72.41
Inventory Days	253.40	331.92	193.84	221.09	146.53
Payable days	43.26	26.16	60.19	37.02	29.05
Cash Conversion Cycle	262.59	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly